The New Synthetic Design And Structural Characterization Of Imida

Overactive bladder is a common chronic urinary tract dysfunction of mo-dern medicine. Overactive bladder patients gradually increase, along with the s-ocial competition and the coming of aging trend, seriously affects the patient’s physical and mental health, reduces the quality of life. According to WHO est-imates, about 40% people around the world have been influenced by the troub-led. At present there are many methods to treat this disease in China, which mainly drug treatment. But the effect of most drugs is not very well. Overacti-ve bladder is attracting more and more attention of doctors and patients. Imid-afenacin is highly selective drugs for bladder, lies in its competitive advantage: it can inhibit bladder smooth muscle contraction and inhibit acetylcholine free double effect, less adverse reactions, can meet the clinical demand increasing.This study chose a series of lead compounds to synthetize the target com-pounds. According to its characteristics and mechanism of action, while retaini-ng its structure, we had done some new design, reduced adverse reaction, and increased the yield. We got intermediate compounds, such as 2-methyl imi-dazole, ethyl bromide two benzene acetonitrile. Take the above intermediate co-mpounds as raw material, we got target compounds through a series of addition reaction. According to the experience of the domestic and foreign synthesis e-xperiment, we chose the experimental route and optimization of synthetic cond-itionns. We chose an economic, simple route of Imidafenacin semi-finished pro-duct synthesis. The target compounds obtained by hydrolysis reaction.The ce-mical structure of the target compound synthesis methods were identified by IR, NMR and X ray powder diffraction and other modern instrumental analysis. The structure of Imidafenacin is 4-(2-Methyl-lH-imidazol-1-yl)-2,2-diphenylbutan amide. In the last century, Japanese applied for the ten years patent protection. The patent expires this year. At present, many domestic companies try to get the right of production and sales. The drug is going to enter Chinese market. This provides reference for Imidafenacin production, research, quality control, structure identification etc.